Almac Group Announces Successful HSA Inspection of Singapore Facility
October 22, 2018
Craigavon, N.I., 22 October 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is pleased to announce it has received a renewal of its GMP/GDP certification following the successful regulatory inspection by the Health Sciences Authority (HSA) of its facility in Singapore.
The organisation’s Asia Pacific headquarters and clinical trial supply facility was first established in Singapore in 2015 and vastly expanded Almac’s range of unique solutions offered from within the region to further optimise the clinical supply chain for both global and regional studies in their customers’ own language and time zones. This accreditation was awarded after an on-site 3 day inspection held in June 2018 confirming Almac’s compliance with the HSA standards of safety, quality and efficacy across its various operations.
Almac has continued to invest in and strengthen its in-region capabilities which are a key part of its ongoing global expansion strategy to meet market and patient needs. As part of this strategy, the facility has seen a 40% uplift in business volume, which has led to the creation of further permanent jobs at our Singapore and Japanese facilities in support of this increased demand. The successful inspection strengthens Almac’s commitment to directly support sponsors conducting regional and global studies by providing clinical manufacturing, packaging, storage, distribution, supply chain management and Interactive Response Technology (IRT).
Paul O’Connor, Global VP Quality, Almac Clinical Services, said: “Almac was the first full service clinical trial packaging and distribution organisation to ever receive GMP certification in this region when we opened our Asia-Pacific Headquarters just 3 years ago. We are delighted to receive today’s official certification which is testament to the quality and skill of our employees. We recognise the global scope, relevance and impact of our sphere of work. This successful inspection echoes our commitment to be a world leader on quality and service wherever we do business.”
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia. Click here to view our facilities.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.